Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol.

Autor: Janssen, J. C.1,2 (AUTHOR), van Dijk, B.1 (AUTHOR), de Joode, K.1 (AUTHOR), Aarts, M. J. B.3 (AUTHOR), van den Berkmortel, F. W. P. J.4 (AUTHOR), Blank, C. U.5,6 (AUTHOR), Boers-Sonderen, M. J.7 (AUTHOR), van den Eertwegh, A. J. M.8 (AUTHOR), de Groot, J. W. B.9 (AUTHOR), Jalving, M.10 (AUTHOR), de Jonge, M. J. A.1 (AUTHOR), Joosse, A.1 (AUTHOR), Kapiteijn, E.6 (AUTHOR), Kamphuis-Huismans, A. M.11 (AUTHOR), Naipal, K. A. T.1 (AUTHOR), Piersma, D.12 (AUTHOR), Rikhof, B.13 (AUTHOR), Westgeest, H. M.14 (AUTHOR), Vreugdenhil, G.15 (AUTHOR), Oomen-de Hoop, E.1 (AUTHOR)
Zdroj: BMC Cancer. 5/23/2024, Vol. 24 Issue 1, p1-7. 7p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje